Navigation Links
Cancer Drug Reduced Relapses in MS Patients: Studies
Date:11/1/2012

THURSDAY, Nov. 1 (HealthDay News) -- The cancer drug alemtuzumab (Campath) reduces the risk of disease relapse in people with multiple sclerosis, two new trials show.

About 85 percent of multiple sclerosis patients start with a form of the disease called relapsing-remitting MS, where symptoms appear sporadically (a relapse) and then either partially or completely fade away. There is no cure for MS, and existing drugs only aim to reduce the symptoms of the disease.

MS occurs when the body's immune system starts to attack the coating of nerve fibers. Alemtuzumab, which is used to treat leukemia and other cancers of the immune system, works by altering the number, proportions and functions of certain types of lymphocytes, which are white blood cells that play a major role in the functioning of the immune system.

In these two clinical trials, British researchers led by Alastair Compston of the University of Cambridge compared alemtuzumab with interferon beta 1a, the most common drug used to treat MS.

The first trial included patients who had never received drug treatment for MS. The relapse rates after two years were 22 percent for those who were given alemtuzumab and 40 percent for those who were given interferon beta 1a.

The second trial included patients who had already been treated with either interferon beta 1a or another MS drug called glatiramer, but had suffered at least one relapse since their initial treatment. The relapse rates were 35 percent for patients who were given alemtuzumab and 51 percent for those who received interferon beta 1a, the investigators found.

The researchers also found that alemtuzumab appeared to reduce the risk of MS-related disability such as the loss of coordination or the ability to walk. Disability rates were 13 percent among those in the alemtuzumab group and 20 percent of those in the interferon beta 1a group. The first trial found no significant difference in disability rates between the two groups of patients.

In both trials, alemtuzumab appeared to increase the risk of certain autoimmune disorders, particularly those affecting the thyroid. These side effects are potentially serious but can be treated, the researchers noted.

The findings were published Oct. 31 in The Lancet.

The findings are "encouraging," according to a journal editorial, which noted that alemtuzumab has been used off-label for many years to treat MS patients.

"These trials have been keenly awaited by clinicians and patients wishing to establish evidence for this practice. . . . However, there is concern that with a license for multiple sclerosis, the cost of alemtuzumab could rise and might become too expensive for many patients [and health systems]," the editorial stated.

"Finding promising treatments such as alemtuzumab is important. But so is keeping alemtuzumab accessible and affordable if its early success in these trials proves to be of enduring value," the editorial concluded.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about multiple sclerosis.

-- Robert Preidt

SOURCE: The Lancet, news release, Oct. 31, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. New Stool Test Might Aid in Early Detection of Colon Cancer
3. Study reveals how cancer drug causes diabetic-like state
4. How a cancer drug leads to diabetes
5. You Survived Cancer: Now Pay Attention to Your Overall Health
6. New drug prevents spread of human prostate cancer cells
7. Eliminating the good cholesterol receptor may fight breast cancer
8. Taller, Heavier Women May Face Higher Ovarian Cancer Risk
9. Experimental Chemo Combo for Colon Cancer Disappoints
10. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
11. Targeted therapeutics for colon cancer to be presented at AACR meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer Drug Reduced Relapses in MS Patients: Studies
(Date:1/17/2017)... ... January 17, 2017 , ... Today, to help ... Francis re-releases powerfully uplifting interview with medical expert and prolific author, Dr. Bernie ... pass through tough times, Dr. Bernie Siegel energizes listeners to live life with ...
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will demonstrate its ... Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention Center in ... the gold standard for high-definition, in-ear earphones. This classic earphone has been updated ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... online continuing education for EMS and firefighting professionals, has released four new continuing ... These new courses are taught live in an online classroom and meet the ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... partnership with Sigfox in the U.S.A. to offer Internet of Things ... new offerings on large-scale environmental sensor deployments such as monitoring solutions used to ...
(Date:1/17/2017)... ... 17, 2017 , ... Livionex, Inc., a Silicon Valley healthcare company focused on ... for its dental gel that shows significant reduction in plaque levels and gum inflammation ... study was conducted at the Beckman Laser Institute at UC Irvine and has been ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Research and Markets has announced the addition of the ... their offering. ... This new report revisits the market potential for self-healing materials from ... 2015. Self-healing is an area of smart coatings and materials with ... potential of $2.7 billion ($US) by 2020. However, in any market ...
(Date:1/17/2017)... TEL AVIV, Israel , January 17, 2017 ... , TyrNovo, Ltd.   KIT-302 Development On ... the FDA in Q1 2017   ... Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: ... a business update call on Monday, January 23 rd at 8:30am Eastern ...
(Date:1/17/2017)... 2017  Edwards Lifesciences Corporation (NYSE: EW ... heart disease and critical care monitoring, plans to announce ... 2016 after the market closes on Wednesday, February 1, ... p.m. ET that day to discuss those results. ... 407-8037 or (201) 689-8037.  For 72 hours following the ...
Breaking Medicine Technology: